Elamipretide Targets Mitochondrial Membranes to Reverse Aging and Disease

Mitochondria are central to cellular energy metabolism, stress signaling, and survival. Their dysfunction is a hallmark of aging and underlies a wide spectrum of chronic diseases. Elamipretide—a small, cell-permeable tetrapeptide with alternating cationic-aromatic residues—selectively localizes to the IMM, where it binds cardiolipin (CL), a unique anionic phospholipid critical for membrane architecture, electron transport, and apoptotic signaling. This review synthesizes over a decade of mechanistic and translational research to reframe how elamipretide works.

The original hypothesis that elamipretide acts primarily as a reactive oxygen species (ROS) scavenger has been largely superseded. Molecular dynamics simulations and NMR studies show that elamipretide interacts with CL-containing bilayers in two states—surface anchoring via electrostatic contacts with phosphate headgroups, and hydrophobic burial of aromatic residues into the membrane core. The net effect is a 'controlled down-tuning' of the negative surface charge density of CL-rich bilayers. This reduces Ca²⁺ interactions with CL, limits cytochrome c peroxidase activity, and alters lipid packing to promote curvature and cristae formation—all upstream of ROS generation.

Chemical cross-linking mass spectrometry identified 12 IMM proteins that directly interact with biotin-tagged elamipretide, all CL-associated. Two interactions stand out. First, elamipretide binds NDUA4, a complex IV subunit whose association with CIV prevents dimer formation and facilitates incorporation into respiratory supercomplexes—structures essential for efficient oxidative phosphorylation. Second, elamipretide cross-links to the matrix face of ANT1 (ADP/ATP translocase 1), reducing ANT1-mediated proton leak, stabilizing mitochondrial membrane potential, and reversing age-related increases in mitochondrial permeability transition pore opening. These interactions also stabilize the ATP synthasome—a supercomplex of ANT, ATP synthase, creatine kinase, and phosphate carrier.

In vivo, these molecular effects translate into measurable functional improvements. In aged rodents, elamipretide rapidly reversed declines in resting and maximal ATP production, improved phosphocreatine-to-ATP ratios, restored redox homeostasis, and improved skeletal muscle force and cardiac pump function. In a randomized placebo-controlled trial in healthy older adults, a single dose increased maximal skeletal muscle ATP production (ATPmax) compared to placebo. In Barth syndrome lymphoblasts and patient-derived cardiomyocytes, elamipretide restored CL levels and respiratory supercomplex assembly. Completed clinical trials in Barth syndrome, primary mitochondrial myopathy, and age-related macular degeneration provide early signals of therapeutic benefit, though results vary by endpoint and population.

Collectively, these data establish elamipretide as a potential first-in-class IMM-targeting therapeutic with a multi-pronged mechanism: electrostatic modulation of CL-rich membranes, stabilization of respiratory and ATP-producing supercomplexes, and reduction of proton leak. Caveats include the complexity of translating mitochondrial biology from rodent models to humans, variability in clinical trial endpoints, and incomplete understanding of how elamipretide's effects differ across tissue types and disease contexts.